Nuvation Bio Inc. $NUVB Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP lifted its stake in Nuvation Bio Inc. (NYSE:NUVB) by 238.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 139,257 shares of the company’s stock after buying an additional 98,158 shares during the quarter. Quantinno Capital Management LP’s holdings in Nuvation Bio were worth $597,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Nuvation Bio by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock worth $191,000 after purchasing an additional 4,608 shares during the period. Millennium Management LLC boosted its holdings in Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after buying an additional 1,298,131 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in Nuvation Bio during the second quarter valued at $92,000. Creative Planning grew its position in Nuvation Bio by 267.1% during the second quarter. Creative Planning now owns 39,288 shares of the company’s stock valued at $77,000 after buying an additional 28,585 shares during the period. Finally, Cetera Investment Advisers purchased a new position in Nuvation Bio in the second quarter valued at $29,000. 61.67% of the stock is owned by institutional investors and hedge funds.

Nuvation Bio Stock Performance

Shares of NYSE:NUVB opened at $7.25 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.37 and a quick ratio of 8.14. The business’s 50 day moving average price is $6.03 and its 200-day moving average price is $5.29. The firm has a market capitalization of $2.54 billion, a PE ratio of -16.47 and a beta of 1.52. Nuvation Bio Inc. has a 1 year low of $2.57 and a 1 year high of $9.75.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $31.69 million during the quarter, compared to analyst estimates of $27.03 million. Nuvation Bio had a negative net margin of 88.18% and a negative return on equity of 46.59%. As a group, equities research analysts expect that Nuvation Bio Inc. will post -0.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Nuvation Bio

In other Nuvation Bio news, Director Robert Mashal bought 25,000 shares of Nuvation Bio stock in a transaction dated Tuesday, June 9th. The stock was acquired at an average cost of $4.73 per share, for a total transaction of $118,250.00. Following the completion of the transaction, the director directly owned 225,000 shares of the company’s stock, valued at approximately $1,064,250. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Philippe Sauvage sold 47,668 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total transaction of $286,484.68. Following the completion of the transaction, the chief financial officer directly owned 12,673 shares in the company, valued at approximately $76,164.73. This represents a 79.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 235,668 shares of company stock worth $1,419,495 over the last three months. 30.11% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Truist Financial raised their target price on Nuvation Bio from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. B. Riley Financial reaffirmed a “buy” rating on shares of Nuvation Bio in a report on Friday, August 7th. HC Wainwright increased their price target on Nuvation Bio from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a research report on Thursday, July 23rd. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.